Dynavax News
Most Popular Dynavax Story
Dynavax tanks on feds' Heplisav stance
Shares of Dynavax Technologies plunged 75 percent after company officials announced that U.S. regulators were asking for more information on its hepatitis B Vaccine and was... Read more...
Latest Headlines
- October 23, 2008
- August 6, 2008
- July 24, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
